Cabozantinib

Drug Profile

Cabozantinib

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Duke University Medical Center; Exelixis; Ipsen; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum
  • Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Phase III Hepatocellular carcinoma
  • Phase II Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Phase I Acute myeloid leukaemia; Cancer; Colorectal cancer; Solid tumours
  • No development reported Astrocytoma; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 09 Sep 2017 Updated efficacy and adverse events data from the phase II CABOSUN trial in Renal Cell Carcinoma released by Exelixis and Ipsen
  • 08 Sep 2017 Launched for Renal cell carcinoma (Late-stage disease, Second-line therapy or greater) in United Kingdom, Spain, Netherlands, Luxembourg, Germany, Denmark, Austria and Norway (PO) before September 2017
  • 08 Sep 2017 Preregistration for Renal cell carcinoma (Late-stage disease, First-line therapy) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top